Members of the XCath team celebrating the successful use of its endovascular robotic system, known as Iris, to treat patients with complex brain aneurysms last year. Screenshot via bussinesswire.com

Robotic neurosurgery is an exciting new frontier in medicine, and Houston-based medtech firm XCath is leading the charge with its revolutionary Iris robotic system. The company announced in March that it had secured $30 million in Series C funding to continue developing systems to tackle blood clots in the human brain.

“We are grateful to our investors for their conviction in our shared mission to improve clinical outcomes for patients impacted by endovascular diseases,” Eduardo Fonseca, CEO of XCath, said in a news release. “In 2025, the XCath team advanced the frontiers of endovascular robotics. This funding accelerates our commitment to expanding access to life-saving care so that where a patient lives no longer determines whether they live.”

XCath–which also has campuses in Pangyo, South Korea–has already achieved a number of remarkable firsts in robotic neurosurgery. The Iris is the only endovascular robotic system currently in development to perform intracranial navigation or neurointerventional treatment, and is the only robot in the world to have performed an intracranial neurovascular procedure involving the robotic manipulation of three devices.

These new Series C funds, which bring the company's total investment to $92 million, will go toward developing a clinical telerobot capable of performing a mechanical thrombectomy. This would bring unprecedented accuracy and precision to the surgical removal of brain clots, significantly reducing the risk of neurosurgery.

“Robotic surgery succeeds when innovation is paired with practical execution,” Dr. Fred Moll, chairman of the XCath board of directors, said in the release. “XCath has built a promising technology foundation, and just as importantly, a team that values rigor and appreciates perspective. I’m excited to support them as they take on the mission of globalizing access to gold-standard care for stroke patients.”

In November 2025, the Iris debuted under the control of Dr. Vitor Mendes Pereira at The Panama Clinic in Panama City, alongside local Principal Investigator Dr. Anastasio Ameijeiras Sibauste. It was only the second time in human history that a robot had been used for intracranial neurovascular intervention, and it established Iris as a viable technology in the fight against stroke.

“Treatment of stroke and other neurovascular diseases represents one of the most significant financial opportunities in healthcare, supported by positive reimbursement dynamics and strong demand from health systems,” Nicholas Drysdale, CFO of XCath, added in the release. “With our continued investor support and disciplined capital deployment, XCath is positioned to build a category-leading platform in endovascular robotics”.

This week's roundup of Houston innovators includes Anwar Sadek of Corrolytics, Angela Holmes of OmniScience, and Eduardo Fonseca of EndoQuest Robotics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across health care and energy.

Anwar Sadek, founder and CEO of Corrolytics

Anwar Sadek of Corrolytics joins the Houston Innovators Podcast to discuss his company's growth and move to Houston. Photo courtesy

Despite having success in taking his technology from lab to commercialization, Anwar Sadek made the strategic decision to move his company, Corrolytics, from where it was founded in Ohio to Houston.

"Houston is the energy capital of the world. For the technology we are developing, it is the most strategic move for us to be in this ecosystem and in this city where all the energy companies are, where all the investors in the energy space are — and things are moving really fast in Houston in terms of energy transition and developing the current infrastructure," Sadek, co-founder and CEO of Corrolytics, says on the Houston Innovators Podcast.

And as big as a move as it was, it was worth it, Sadek says.

"It's been only a year that we've been here, but we've made the most developments, the most outreach to clients in this one last year." Continue reading.

Angela Holmes, CEO of OmniScience

Angela Holmes is the CEO of OmniScience. Photo via omniscience.com

Houston data science firm OmniScience announced this month that it has partnered with Florida-based INmune Bio (NASDAQ: INMB) on a global Phase 2 Alzheimer’s disease clinical trial.

The trial, known as ADO2, will utilize OmniScience's recently developed product, Vivo, which uses generative AI to centralize and analyze clinical trial data in real time, according to a release. The two companies also partnered during Vivo’s development and recent roll-out.

"OmniScience and INmune Bio share a vision to transform how clinical trial teams engage with data – transforming data into knowledge in real time and informing decisions that increase the probability of success,” Angela Holmes, CEO of OmniScience, says in a statement. “As our partnership moves forward, we’re gaining further insights from the INmune team that we can integrate into Vivo’s roadmap. We look forward to our continued mutual success.” Continue reading.

Eduardo Fonseca, interim CEO of EndoQuest Robotics

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via LinkedIn

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap. Continue reading.

EndoQuest Robotics secured an Investigational Device Exemption from the FDA for its clinical study. Photo via Getty Images

FDA greenlights Houston surgery robotics company's unique technology

headed to clinical trials

A Houston surgical robotics company has gotten a Investigational Device Exemption from the FDA to go forward with human trials.

This news allows EndoQuest Robotics to begin its Prospective Assessment of a Robotic-Assisted Device in Gastrointestinal Medicine (PARADIGM) study, which will be conducted at leading United States health care facilities, including Brigham and Women’s Hospital (Boston), Mayo Clinic (Scottsdale), Cleveland Clinic (Cleveland), AdventHealth (Orlando), and HCA Healthcare (Houston). The study will include surgeries on 50 subjects, who will hopefully begin to enroll in January.

“The foundational thesis is we're trying to make sure that the world's largest medical center is also the world's largest med tech innovation center,” Eduardo Fonseca, interim CEO of EndoQuest Robotics, tells InnovationMap.

His company is well on its way to helping to assure that, through making history of its own. EndoQuest is behind the world's first Flexible Robotic Surgical System, a technology that may one day transform surgery as we know it.

The idea to use these novel robots for surgery came from Dr. Todd Wilson, a surgeon at UTHealth Houston, who spent his medical education, residency, and fellowship at the institution.

“I had really focused in my practice on trying to do everything possible to improve outcomes for patients,” Wilson explains. “And there seemed to be a pretty good correlation that the smaller the incisions or the fewer incisions, the better patients would do.”

The stumbling block? The necessary small incisions are difficult for human surgeons to make with current technology. But UTHealth was part of the solution.

“Right there in the University of Texas was a microsurgical lab where they were focusing on trying to develop robotics, but the application was still a little bit fuzzy,” Wilson says.

Using their innovations to solve Wilson’s problem turned out to be the start of the company now known as EndoQuest Robotics.

The first indication for the system is for colon lesions. But in the future it could be used for practically any minimally invasive surgery (MIS). That means that the robots could help to perform anything from a tonsillectomy to cholecystectomy (gallbladder removal) to non-invasive colorectal procedures, should those lesions prove to be cancerous.

According to Fonseca, last year was the first on record that there were more MIS, including laparoscopic and robotic surgeries, than conventional ones in the U.S. The time is right to forge ahead with the flexible robotic surgical system. Days ago, the EndoQuest team announced that its Investigational Device Exemption (IDE) application for its pivotal colorectal clinical study was approved by the FDA.

“Our end point is a device that can be mass-manufactured and very safe for patients and has a short learning curve, so therefore, we intend to learn a lot during these trials that will inform our ultimate design,” says Fonseca.

He adds that it’s a “brilliant” group of engineers that has set EndQuest apart, including both teams in Houston and in South Korea.

“We can move twice as fast as anyone else,” jokes engineer Jiwon Choi.

Despite the extra brain power provided by the South Korea engineers, Fonseca says that EndoQuest’s beginnings are “as much of a Houston story as you could find.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

MD Anderson president to retire after nine years, interim successor named

retirement plan

An era is ending at The University of Texas MD Anderson Cancer Center.

On Aug. 26, Dr. Peter WT Pisters announced his plans to retire from his role as president of the comprehensive cancer center. He will work on a smooth transition of leadership with interim president Dr. Jeffrey E. Lee throughout September.

“I first arrived at UT MD Anderson 32 years ago with a passion for doing everything I could to advance our mission to end cancer. Serving as the only faculty member to become president, and now marking nine years in the role, I can say with great pride and gratitude that there is no better place than UT MD Anderson to turn hope into healing for patients and families everywhere,” Pisters said in a news release. “With a timeless strategy, a strong leadership team, unprecedented levels of financial health, and a priceless culture anchored in our deeply held Core Values, now is the right time for me to transition to other opportunities. UT MD Anderson has never been stronger, and its future has never been brighter.”

Pisters assumed the presidency in 2017 and helped launch some of the most cutting-edge new clinics in MD Anderson history. One of those was the James P. Allison Institute, named for the Nobel Laureate scientist who discovered a way to suppress immune response on tumors so that immune cells would attack cancer cells instead. As head of his titular clinic, Allison pioneered several new immunotherapies against cancer.

Pisters also oversaw the creation of the Institute for Data Science in Oncology in 2024, an innovative consortium of scientists dedicated to enhancing single-cell imaging to improve precision in cancer treatments. The institute also brought together teams to use data-driven analytics regarding safety, quality and access.

The UT System Board of Regents praised the leadership and work of Pisters in a statement, wishing him well in the next phase of his career.

“The Board of Regents and I are profoundly grateful to Dr. Pisters for his exceptional presidency over the past nine years and for thoughtfully concluding his service when UT MD Anderson is thriving at its best position of peak performance, strength and impact. We wish him our very best with his retirement and in his next chapter,” Kevin P. Eltife, chairman of the UT System Board of Regents, added in the release.

Houston e-commerce giant Cart.com launches government-focused subsidiary

government branch

Houston e-commerce and logistics unicorn Cart.com has launched a new subsidiary.

Cart Government Solutions (CGS), which was announced earlier this week, will provide supply chain and logistics services and software for the federal and state government sectors. The new subsidiary will be headquartered in Washington, D.C., and operate out of about 6 million square feet of secure warehouse space across 14 U.S. facilities, according to a news release from Cart.com. It will support both domestic and overseas logistics.

Industry veteran Gregg Zegras will lead the new entity as president. Zegras previously served as Cart.com's chief revenue officer, according to LinkedIn. Before that, he served as president of Connecticut-based Pitney Bowes Global eCommerce, a digital shipping solutions company.

Remington Tonar, Cart.com's co-founder, will serve as CGS's chief innovation officer.

“Government agencies face procurement and logistics challenges that many commercial platforms simply weren’t built to solve,” Zegras said in the news release. “Cart Government Solutions exists to change that. We’re combining the speed and innovation of a technology company with the compliance rigor, security, and operational depth that federal and state customers require, and we’re doing it with a team that has spent careers working alongside and inside these agencies.”

According to the company, CGS will focus on meeting compliance and security requirements in the public sector. Some of the services the new entity will offer include:

  • Inventory management
  • Cold-chain and specialty storage for pharmaceuticals, medical devices and regulated goods
  • Enterprise-grade supply chain software
  • Government-compliant webstores and online ordering portals
  • Cybersecurity operations

Cart.com has been serving the public sector since 2022, when the company began distributing COVID-19 health supplies nationwide, according to the news release. Through that pandemic-era contract, the company reports it moved more than 725 million units, with an average of under two days per shipment.

Cart.com was founded in Houston in 2020, though it briefly moved its headquarters to Austin. The company reached unicorn status with its $60 million Series C raise in 2023. It most recently raised $180 million in growth capital from private equity firm Springcoast Partners in March, which put the startup over the $1 billion in fundraising mark in just six years.

At the time, Cart.com said it planned to scale its logistics network, expand AI capabilities and develop workflow automation tools.

Houston-based KBR Inc. also recently launched a government services spinoff. Read more here.

2 Houston universities named best colleges of 2027 by Princeton Review

A-Plus Ratings

Back-to-school season is has returned in full force, and that means it's time for college rankings. Two Houston universities in particular are being hailed as the top of the class for 2027.

The high caliber schools — Rice University and University of Houston — earned new acclaim in The Princeton Review's ranking of the "Best 392 Colleges" for 2027.

The Princeton Review's 35th annual "Best Colleges" rankings are determined by a survey of 172,000 current college students that gave "candid feedback" about their schools and their experiences. The flagship guide does not rank the schools overall, but it does rank them across 50 different categories, including best-run colleges, best quality of life, happiest students, best athletic facilities, among others.

In all, 14 Texas institutions were highlighted in the overall list of the 392 best colleges.

Schools don't pay to be included in the guide, but The Princeton Review clarified that schools could pay for a "featured" designation. No Houston university paid to be featured in this year's guide. Trinity University in San Antonio and Southwestern University, a private school in the Austin suburb Georgetown, were the only two Texas schools that paid to be "featured."

Rice and UH have been on a winning streak in separate reports of the best universities worldwide, best graduate schools, and best online degree programs.

In addition to being included in the overall list, Rice was highlighted as one of the Best Value Colleges, Colleges That Create Futures, and it earned high marks in Princeton Review's Mental Health Honor Roll 2026. The home of the Rice Owls also starred in the regional Best Southwest list that contained 41 universities across Arizona, Colorado, New Mexico, Oklahoma, and Texas.

"Rice University stands out as a leading research university where academic diversity and a wide array of interdisciplinary institutes and centers make it easy for students to explore multiple areas of interest," the school's profile says. "At Rice, 'knowledge isn’t siloed — students are constantly crossing disciplines and interests in ways that feel natural rather than exceptional.'"

Rice earned the following rankings on 14 other lists:

  • No. 1 – Lots of Race/Class Interaction
  • No. 3 – Best College Newspaper
  • No. 9 – Friendliest Students
  • No. 11 – Best Quality of Life
  • No. 13 – Great Financial Aid
  • No. 14 – Top 50 Best Value Private Colleges
  • No. 17 – Their Students Love These Colleges
  • No. 18 – Top 20 Best Value Private Colleges Without Aid
  • No. 18 – Best Student Support and Counseling Services
  • No. 19 – Best College Dorms
  • No. 21 – Students Study the Most
  • No. 24 – Best Campus Food
  • No. 24 – Best College Radio Station
  • No. 24 – Best-Run colleges
The University of Houston also appeared in the Best Southwest, Best Value Colleges, and Colleges That Create Futures lists, and it was named a top Green College, which examined schools that "share superb sustainability practices, a strong foundation in sustainability education, and a healthy quality of life for students on campus

UH earned five more accolades:

  • No. 1 – Top 50 Undergraduate Schools for Entrepreneurship Studies
  • No. 1 – Top Undergraduate Schools for Entrepreneurship Studies in the Southwest
  • No. 8 – Most Politically Moderate Students
  • No. 15 – Financial Aid Not So Great
  • No. 42 – Top 50 Best Value Public Colleges
In the school's profile, students say they had an overall positive experience thanks to UH's excellent academic offerings and dedicated faculty members.

"Students confirm that 'the research and other academic opportunities... are very accessible to students who seek it out,'" the profile says. "This includes taking advantage of UH’s vast alumni network (more than 325,000 and counting), not to mention its location in the corporate center of Houston, where 'the opportunities that are provided are immense.'"

The 12 other public and private universities in Texas included in The Princeton Review's 2027 guide are:

  • The University of Texas at Austin
  • Southwestern University, Georgetown
  • Baylor University, Waco
  • Texas A&M University - College Station
  • Trinity University, San Antonio
  • Texas State University, San Marcos
  • Angelo State University, San Angelo
  • Texas Christian University, Fort Worth
  • University of Dallas, Irving
  • Southern Methodist University, Dallas
  • The University of Texas at Dallas, Richardson
  • Austin College, Sherman
---

A version of this story originally appeared on CultureMap.com.